Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.79 +0.39 (+2.24%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Sarepta Therapeutics Stock Crashes After-Hours On DMD Trial Failure, Q3 Print — Retail Still Sees Long-Term Comeback ↗

November 03, 2025

Via Stocktwits

Sarepta Therapeutics Stock Is Tumbling After The Close: Here's Why ↗

November 03, 2025

Sarepta shares are plunging in extended trading Monday after the company reports third-quarter results and provided an update on its ESSENCE study.

Via Benzinga

These stocks are moving in today's after hours session ↗

November 03, 2025

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests ↗

November 03, 2025

Sarepta stock crashed Monday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 03, 2025

Via Benzinga

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

A Peek at Sarepta Therapeutics's Future Earnings ↗

October 31, 2025

Via Benzinga

Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗

November 03, 2025

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.

Via Benzinga

Tradr Unleashes 2X Single-Stock Gold ETFs, Reshaping Short-Term Gold Investment Landscape

October 23, 2025

New York, NY – October 23, 2025 – Tradr, a prominent innovator in the Exchange-Traded Fund (ETF) market, has today significantly expanded its product suite with the launch of nine new single-stock 2X...

Via MarketMinute

Tradr Launches 9 Single-Stock 2X ETFs With First-Of-Its-Kind OpenDoor, Gold And AI Exposure ↗

October 23, 2025

The new ETFs include the first-of-their-kind gold and AI plays, giving traders targeted exposure without using margin or complex options.

Via Benzinga

Topics Artificial Intelligence ETFs

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF ↗

October 23, 2025

Funds seek to provide 200% long exposure on a variety of industry leaders

Via Stocktwits

Topics ETFs

What's Going On Sarepta Stock On Wednesday? ↗

October 08, 2025

Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.

Via Benzinga

Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket ↗

October 08, 2025

Investors turned upbeat ahead of Sarepta’s data presentations in Vienna, where the company is expected to share new Duchenne muscular dystrophy results and updates from its broader gene therapy...

Via Stocktwits

Topics Death

Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data

October 03, 2025

Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant...

Via MarketMinute

Taysha Gene Therapies, Canaan, Ondas Holdings And Other Big Stocks Moving Higher On Thursday ↗

October 02, 2025

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

Via Benzinga

Topics Stocks

Incannex Healthcare (NASDAQ: IXHL) Braces for Volatility as Q4 Earnings Loom: Options Traders Eye Strategic Plays

September 27, 2025

Melbourne, Australia – September 27, 2025 – Incannex Healthcare Limited (NASDAQ: IXHL) is on the cusp of a pivotal week, with its Q4 2025 earnings report scheduled for release on Monday, September 29,...

Via MarketMinute

Topics Artificial Intelligence Earnings

This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

September 22, 2025

Via Benzinga

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Expert Outlook: Sarepta Therapeutics Through The Eyes Of 43 Analysts ↗

September 15, 2025

Via Benzinga

2 Beaten-Down Stocks to Avoid Right Now ↗

September 05, 2025

These once high-flying stocks no longer seem to have promising prospects.

Via The Motley Fool

EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank? ↗

September 02, 2025

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Via Benzinga

Forecasting The Future: 44 Analyst Projections For Sarepta Therapeutics ↗

August 25, 2025

Via Benzinga

Sarepta Just Got A Good Restructuring Deal For $700M Debt, But Stock Tumbles 7% – Here’s Why ↗

August 21, 2025

Although the company has managed to push back the maturity of the new debt to 2030, it is also offering cash and common stock to certain investors as part of the deal.

Via Stocktwits

What's Going On With Sarepta Shares Thursday? ↗

August 21, 2025

Via Benzinga

Citi Believes FDA May Closely Watch Sarepta’s Safeguards For Gene Therapy In Non-Ambulatory DMD Patients ↗

August 20, 2025

The firm said that the FDA may determine that additional steps beyond Siromilus are recommended or required for non-ambulatory Duchenne muscular dystrophy patients on Elevidys.

Via Stocktwits

Topics Death

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week ↗

August 14, 2025

H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.

Via Stocktwits

Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives ↗

August 14, 2025

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the company.

Via Investor's Business Daily

Topics Death

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial ↗

August 14, 2025

Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.

Via Stocktwits

How Do Investors Really Feel About Sarepta Therapeutics? ↗

August 13, 2025

Via Benzinga

Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside ↗

August 12, 2025

Per two Wall Street analysts, one of 2025's biggest losers could be set up for a stunning recovery. They see over 175% upside in Sarepta Therapeutics.

Via MarketBeat

Topics Death

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

Headline News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today